Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 52 clinical trials
[Remote] The Impact of Emotions on Social Distancing Adherence and Caregiver Self-efficacy among Caregivers for individuals with Alzheimer’s disease or related dementias during the COVID-19 Pandemic

The purpose of this research study is to understand the factors (e.g., feeling unhappy, lonely, frustrated) that influence compliance with social distancing recommendations during the COVID-19 pandemic. In addition, this study aims to understand how negative emotions (e.g., feeling unhappy, lonely, frustrated) along with social distancing requirements influence family caregivers’ …

  • 29 Apr, 2021
  • 244 locations
R33: Levetiracetam in Early Psychosis

the hypotheses that adding levetiracetam will improve psychotic symptoms that are unresponsive to antipsychotic treatment and will protect the brain from atrophy (volume loss). .

  • 31 Aug, 2021
  • 1 location
A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis

In the first year of treatment after a FE of SCZ, 75% to 90% of patients achieve remission from psychotic symptoms. However, approximately 40% of FE patients are non-adherent to

delusional disorder
cognitive therapy
schizophreniform disorder
psychotic symptoms
  • 07 Nov, 2020
  • 1 location
Repetitive Transcranial Magnetic Stimulation in Early Psychosis and The Functional Connectivity Biotypes

which the patients present psychotic symptoms (positive symptoms, negative symptoms) and cognition deficits. Antipsychotics are often prescribed to treat these symptoms, but more than one third patients

  • 02 May, 2021
  • 3 locations
Deep Transcranial Magnetic Stimulation for the Treatment of Treatment Resistance Schizophrenia

Based on the hypothesis that low-frequency deep transcranial magnetic stimulation(dTMS) on anterior cingulate cortex ACC could down-regulate the glutamate level of ACC and regulate the acc-related functional network in patients with treatment resistance schizophrenia,this research plan to utilise multimodal functional magnetic imaging method(including structural MRI,resting-state functional magnetic resonance imaging and …

  • 19 Sep, 2021
  • 1 location
Understanding of Psychotic Disorders in Children With 22q11.2DS

The study PremiCeS22 will investigate the prodromal signals at the onset of psychotic disorders of children with 22q11.2 deletion syndrome

  • 26 Jan, 2021
  • 1 location
Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy

Recent studies have established the reliability, validity and time course of the cannabis withdrawal syndrome. This study will investigate the effects of combined treatment of Escitalopram with cognitive-behavior therapy in alleviating the symptoms of the marijuana withdrawal syndrome in regular chronic users of marijuana. We predict that combined pharmacological treatment …

cannabis withdrawal
withdrawal symptoms
  • 07 Nov, 2020
  • 1 location
Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome

Chromosome 22q11.2 deletion syndrome (22q11DS) is a neurogenetic condition associated with a high risk of psychiatric disorders, including schizophrenia spectrum disorders. This population is characterized by a particular neurocognitive profile and atypical brain development. Risperidone is a second-generation antipsychotic, inhibitor of dopaminergic receptors. Used in the treatment of psychosis, risperidone …

  • 26 Jan, 2021
  • 1 location
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)

This is a randomized, double-blind, placebo-controlled, multi-centre trial. A total of 300 CHR subjects will be identified in the course of face-to-face interviews using the Structured Interview for Prodromal Syndromes. All participants will be randomly allocated to SFN group (n = 150) or placebo group (n = 150). The study …

  • 25 Jan, 2021
  • 11 locations
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

50 healthy volunteers (HV) will participate in 2 identical ketamine-induced pharmacoBOLD (phBOLD) sessions at least 7 days apart. On both days, clinical assessments will be performed following removal of the subject from the scanner. HV will be discharged home after clearance by the study physician. This study will assign ketamine …

  • 28 Jan, 2021
  • 1 location